Skip to main content

Table 1 Patient characteristics at baseline

From: Investigation into cardiac sympathetic innervation during the commencement of haemodialysis in patients with chronic kidney disease

  Frequency, median (range) or mean ± standard deviation
Gender (number)
 Male 13 (72%)
 Female 5 (28%)
Age (years) 58 ± 18
Medical history (number)
 Hypertension 14 (78%)
 Hypercholesterolemia 6 (33%)
 Diabetes mellitus 6 (33%)
 Smoking 2 (11%)
 Coronary artery disease 0 (0%)
Medication at baseline (number)
 β-blockers 11 (61%)
 ACE ihibitors 6 (33%)
 Diuretics 8 (44%)
Laboratory at inclusion
 Leucocytes (× 109/l) 7.1 (3.3–9.8)
 Haemoglobin (mmol/l) 6.8 (6.0–9.7)
 Trombocytes (× 109/l) 208 (117–347)
 C-reactive protein (mg/l) 0 (0–59)
 Sodium (mmol/l) 140 (135–145)
 Potassium (mmol/l) 4.9 (4.0–5.9)
 Chloride (mmol/l) 107 (98.0–114)
 Urea (mmol/l) 26 (15–38)
 Creatinine (μmol/l) 584 (339–1.31 × 103)
 eGFR (ml/min × 1.73 m2) 8.0 (4.0–12)
 Uric acid (mmol/l) 0.45 (0.23–0.72)
 Calcium (mmol/l) 2.25 (2.07–2.53)
 Phosphate (mmol/l) 1.60 (1.07–2.12)
 Total protein (g/l) 67 (60–77)
 Albumin (g/l) 41 (29–46)
 High-density lipoprotein cholesterol (mmol/l) 1.0 (0.70–2.7)
 Low-density lipoprotein cholesterol (mmol/l) 2.2 (0.80–4.8)
 Glucose (mmol/l) 6.7 (4.1–14)
 Urinary protein excretion (g/24 h) 2.7 (0.40–6.8)
  1. ACE angiotensin converting enzyme, eGFR estimated glomerular filtration rate